Both will develop cancer vaccine candidates in selected haematological and solid tumour indications
Category: solid tumour cancer
Solid tumour cancers account for 90% of adult human cancers and 50% of childhood malignancies
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359